197 related articles for article (PubMed ID: 15466129)
21. Letter to the editor: Comment on 'Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder'.
Olders H
J Pediatr Psychol; 2009; 34(1):108-9; author reply 110-2. PubMed ID: 19136567
[No Abstract] [Full Text] [Related]
22. [Central nervous system stimulants in AD/HD in adults].
Aanonsen NO; Lensing MB; Mathiesen T
Tidsskr Nor Laegeforen; 1999 Jan; 119(1):82-3. PubMed ID: 10025211
[No Abstract] [Full Text] [Related]
23. Transdermal methylphenidate system: old wine in a new bottle.
Bukstein OG
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):661-5. PubMed ID: 19442029
[TBL] [Abstract][Full Text] [Related]
24. [Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders].
Aanonsen NO
Tidsskr Nor Laegeforen; 1999 Nov; 119(27):4040-2. PubMed ID: 10613094
[TBL] [Abstract][Full Text] [Related]
25. Status epilepticus associated with the administration of long-acting methylphenidate in a 7-year-old girl.
Goetz M; Surman CB; Mlynarova E; Krsek P
J Clin Psychopharmacol; 2012 Apr; 32(2):300-2. PubMed ID: 22388167
[No Abstract] [Full Text] [Related]
26. Newly approved once-daily formulations of medications for the treatment of Attention Deficit (Hyperactivity) Disorder (ADHD) in children and adolescents.
Roman MW
Issues Ment Health Nurs; 2010 Aug; 31(8):548-9. PubMed ID: 20624025
[No Abstract] [Full Text] [Related]
27. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children: A viewpoint by Raul R. Silva.
Silva RR
Drugs; 2006; 66(8):1127-8; discussion 1128. PubMed ID: 16789798
[No Abstract] [Full Text] [Related]
28. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
29. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A; Richard C; Prinzo R; Binder C
Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
[TBL] [Abstract][Full Text] [Related]
30. Transdermal methylphenidate (Daytrana) for ADHD.
Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
[No Abstract] [Full Text] [Related]
31. The effect of methylphenidate on response inhibition and the event-related potential of children with attention deficit/hyperactivity disorder.
Broyd SJ; Johnstone SJ; Barry RJ; Clarke AR; McCarthy R; Selikowitz M; Lawrence CA
Int J Psychophysiol; 2005 Oct; 58(1):47-58. PubMed ID: 15925419
[TBL] [Abstract][Full Text] [Related]
32. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.
González MA; Campbell D; Rubin J
J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):227-32. PubMed ID: 19519257
[TBL] [Abstract][Full Text] [Related]
33. Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder.
Elia J; Wilson Z; La Porta LS; Algon SA; Prowler ML; Cartwright ST; McKenna PA; Laracy S; Takeda T; Borgmann-Winter K
Expert Rev Clin Pharmacol; 2011 May; 4(3):311-28. PubMed ID: 22114778
[TBL] [Abstract][Full Text] [Related]
34. [Methylphenidate of retard forms in children and adolescents with ADHD - an overview].
Pelz R; Banaschewski T; Becker K
Klin Padiatr; 2008; 220(2):93-100. PubMed ID: 18157763
[TBL] [Abstract][Full Text] [Related]
35. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
[No Abstract] [Full Text] [Related]
36. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
[TBL] [Abstract][Full Text] [Related]
37. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
38. A new way to deliver psychiatric meds.
Levin-Epstein M
Behav Healthc; 2006 Aug; 26(8):22-3. PubMed ID: 16961036
[No Abstract] [Full Text] [Related]
39. Cardiovascular effects of methylphenidate.
Daniels SR
J Pediatr; 2009 Jul; 155(1):A3. PubMed ID: 19559283
[No Abstract] [Full Text] [Related]
40. Comments on effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation study.
González MA; Polli JE; Morgan JA
Curr Med Res Opin; 2002; 18(7):vii-x. PubMed ID: 12487510
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
